|Bid||27.41 x 1100|
|Ask||28.08 x 900|
|Day's Range||27.91 - 28.60|
|52 Week Range||25.24 - 61.59|
|Beta (5Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.00|
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.
Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed an agreement with Invitae Corporation, a leader in medical genetics, to bring Invitae's genetic testing services to Volpara's customers in the United States.